The Need to Define the Substances Measured in Tests for Cytokeratins

Mellerik D.M. , Osborn M. , Weber K. On the nature of serological tissue polypeptide antigen (TPA): monoclonal keratin 8, 18, 19 antibodies react differently with TPA prepared from human cultured carcinoma cells and TPA in human serum. Oncogene 1990; 5: 1000–17.

Sundstroem B. , Brundell B. , Stigbrand T.I. , Hansson L.O. , Bombardieri E. Cytokeratins and cancer. J Turn Marker Oncol 1993; 8: 43.

Bjorklund B. Tumor markers TPA, TPA-S and cytokeratins. Tumordiagn u Ther 1992; 13: 78–80.

Bodenmuller H. Personal communication at the Meeting on Cytokeratins, National Cancer Institute, Milan, 18th March 1993.

Wiklund B. , Silen A. , Nilsson S. , Andersson E-L. Cytokeratin 8 and 18 quantified in serum of healthy individuals and pancreatic cancer patients with a novel monoclonal assay. J Turn Marker Oncol 1993; 8: 46.

Bodenmuller H. , Ofenloch-Haehlne B. , Banauch D. , Dessauer A. Lung cancer associated cytokeratin 19 fragments: Biochemical background of the serum assay Cyfra 21–1. J Turn Marker Oncol 1993; 8: 46.

Ballesta A.M. , Torre G.C. , Bombardieri E. , Gion M. , Molina R. , eds. Updating on tumor markers in tissues and in biological fluid. Torino: Minerva Medica 1993.

Stieber P. , Hasholzner U. , Bodenmuller H. Cyfra 21–1. A new marker for lung cancer. Cancer 1993; 72: 707–13.

Correale M. , Arnberg H. , Blockx P. A new monoclonal antibody based immunoassay for tissue polypeptide antigen. Preliminary clinical results. J Turn Marker Oncol 1993; 8: 72.